Floatz logo

Selpercatinib

Recurrent Osteosarcoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

58 Active assets in the Recurrent Osteosarcoma cohort.

Asset / SponsorPhaseRating
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
(+)-VINCRISTINE
Milton S. Hershey Medical Center
Phase 2BB
Ipilimumab
Children's National Research Institute
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Selpercatinib is also rated in:

medullary thyroid gland carcinomaDormant
B
Indicative ·
60 / 100
View asset →
soft tissue sarcomaDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →